US Patent 7,625,884: What Is Claimed and How It Stacks in the US Balsalazide Landscape
What does US 7,625,884 claim, in plain technical scope?
US Patent 7,625,884 claims a method of treating gastrointestinal disorders by administering balsalazide with food, where the key limitation is the timing of dosing relative to eating and the observed pharmacokinetic consequences (increased delivery and exposure to the colon).
Core independent claim (Claim 1)
Claim 1 requires all of the following elements:
-
Indication / method context
- “A method of treating a gastrointestinal disorder”
- “Administering to a subject in need of treatment”
-
Drug
-
Food administration and timing
- Administer balsalazide with food
- The “administering with food comprises administering balsalazide within 15 minutes after eating a meal”
-
Outcome requirement (PK/PD proxy)
- Administration “results in an increase in bioavailability of:
- balsalazide and
- metabolites 5-aminosalicylic acid (5-ASA) and N-acetyl-5-ASA (NASA)
- and specifically increases bioavailability “to the colon”
- compared to fasted-state administration
Scope anchor: The novelty sits in the combination of (i) timing within 15 minutes of a meal and (ii) colon-targeted bioavailability increase for balsalazide and 5-ASA/NASA versus fasted dosing.
What narrowing limitations expand or constrain the claim set?
Claim 2: printed labeling and specific food-effect directions
Claim 2 depends on Claim 1 and adds a labeling-based limitation tied to food administration outcomes.
It recites dosing from a “container with printed labeling” advising that food administration results in one or more of the following:
- Delay of transit of balsalazide, 5-ASA, or NASA in the colon
- Decrease in systemic levels of one or more of 5-ASA or NASA
- Decrease in maximal plasma concentration (Cmax) of one or more of balsalazide/5-ASA/NASA
- Delaying Tmax
- Decreasing extent of absorption (AUC_last)
- Increasing conversion:
- balsalazide to 5-ASA
- and 5-ASA to NASA
- Increasing systemic ratio of NASA to 5-ASA
Practical construction impact: Claim 2 adds a regulatory/consumer-facing labeling requirement plus a list of food-effect PK markers. It can matter for enforcement because it turns an activity (method dosing) into one that must match how product instructions warn about the food-timing effect.
Claim 3: informing the subject
Claim 3 depends on Claim 1 and requires an additional step:
- “Informing the subject that” administration with food in a pharmaceutical composition
- results in increased bioavailability of balsalazide and metabolites 5-ASA and NASA
Scope impact: This claim adds a behavioral/communication step that can support enforcement against actors who control patient instructions (e.g., product labeling, patient counseling).
Claims 4 to 7: dosage amount and regimen embodiments
These claims define therapeutically effective amounts and specific daily regimens.
Claim 4 (dose ranges)
- about 6.25 mg to 14,000 mg/day, or
- about 750 mg to 6,750 mg/day, or
- about 1,100 mg to 13,200 mg/day
Claims 5 to 7 (regimen examples)
- Claim 5: three capsules three times each day, each capsule ~750 mg
- Claim 6: three tablets two times each day, each tablet ~1,100 mg
- Claim 7: one capsule three times each day, each capsule ~750 mg
Scope impact: These embodiments enlarge coverage to multiple dosing formats while preserving the timing and colon-bioavailability outcome of Claim 1. Any product design that fits these ranges can still be within scope if the other Claim 1 limitations are met.
Claim 8: specified foods
Claim 8 depends on Claim 1 and defines food as including one or more of:
- applesauce, or
- a high-fat meal
Scope impact: This helps establish that “with food” is not limited to generic food; it includes specific exemplified food categories. If a product or clinical protocol uses a “high-fat meal” or apple-based vehicle to induce the claimed effect, it tracks Claim 8 closely.
Claim 9: gastrointestinal disorder coverage
Claim 9 expands the method’s therapeutic target list to include:
- mild to moderately active ulcerative colitis
- radiation proctosigmoiditis
- colon cancer
Scope impact: It is a broad therapeutic universe within gastrointestinal diseases, covering both inflammatory bowel indications and oncology.
What is the practical claim “shape” for infringement risk?
US 7,625,884 is structured around a patient dosing instruction protocol:
- When to dose: within 15 minutes after eating
- What to administer: balsalazide
- What to expect: increased colon bioavailability of balsalazide, 5-ASA, NASA relative to fasting
- Optional add-ons: labeling, informing, specific foods, specific dose regimens
This is not a claim about a new chemical entity or new dosage form by itself. It is a method claim keyed to timing and colon delivery outcomes.
How does this fit into the broader US balsalazide patent landscape?
A complete, defensible “patent landscape” typically requires named patent family members, expiration dates, and active claim sets across jurisdictions. Only the claim text provided is available here, so the landscape analysis below is restricted to structural positioning: where this patent sits in the typical bargaining space of balsalazide (oral 5-ASA prodrug systems), and what claim features tend to overlap with other US filings.
Where US 7,625,884 sits within common balsalazide IP themes
In the US, balsalazide IP historically clusters into:
- Formulation/process protection (how the prodrug is made or delivered)
- Dosage form and administration regimen protection (capsules/tablets, dosing frequency)
- Patient instructions and timing methods (food effects, meal timing, intake rules)
- Pharmacokinetic and colon-targeting claims (colon delivery, reduced systemic exposure, conversion patterns)
- Therapeutic method claims across GI indications (ulcerative colitis, proctosigmoiditis, etc.)
US 7,625,884 most strongly aligns with the patient instruction and food-timing / colon delivery cluster:
- the “within 15 minutes” restriction and
- the “increase bioavailability to the colon” outcome metric.
Likely overlap hot spots
Even without enumerating every US family member, the claim language identifies where infringement risk overlaps with other patents or where competitors seek “workarounds”:
-
Meal-timing window
- The explicit cutoff: ≤15 minutes
- Workaround axis in later filings often uses dosing windows like “with food” but outside a narrow post-meal interval.
-
Outcome framing
- Claim 1 requires increased colon bioavailability for:
- Competitors can attempt to argue:
- no comparable increase “to the colon,” or
- different metabolic/absorption profile.
-
Food category
- Claim 8 names applesauce and high-fat meal.
- Protocols that use different vehicles or that avoid high-fat/defined vehicles can be used to reduce match strength, depending on claim interpretation.
-
Labeling and patient instruction steps
- Claims 2 and 3 introduce labeling and informing steps.
- If another product’s labeling does not advise the specific food-timing relationship or expected PK shifts, it can reduce or reshape exposure, depending on how courts treat method instruction claims tied to label content.
-
Dose regimen variants
- Claims 4-7 cover multiple capsule/tablet regimens at defined strengths.
- Competitors using different dose strengths or regimen schedules might aim to step outside the recited regimens, though Claim 4’s broad day ranges can still sweep in.
Enforcement-relevant claim interpretation signals
From a business perspective, the enforceable “deal terms” of US 7,625,884 are concentrated in interpretive levers:
1) What counts as “with food”
- Claim 1 does not require a specific food composition.
- Claim 8 provides exemplars (applesauce, high-fat meal), suggesting “with food” includes vehicles capable of modulating gastric/intestinal transit and/or absorption.
2) What counts as “within 15 minutes after eating”
- This is an objective timing parameter tied to meals.
- It can drive a compliance-based protocol, including how meals are defined and how dosing time is recorded.
3) “Increase in bioavailability … to the colon”
- The claim is outcome-bound and compares to a fasted state.
- The measurement method is not in the excerpt, but the result is required to be demonstrable.
4) “Bioavailability and metabolites”
- Claim 1 explicitly covers:
- That breadth can pull in protocols optimized for colon delivery of any of these analytes, if the overall “increase” requirement is satisfied for the set claimed.
Risk map: which parties face the tightest exposure
Given the claim form, exposure typically concentrates around parties controlling patient instructions and dosing protocol implementation:
- Brand and generic manufacturers whose labeling or patient instructions reflect the claimed meal-timing advice (Claims 2-3).
- Marketing and REMS-like patient education channels that “inform the subject” the claimed PK effect occurs with food dosing (Claim 3).
- Clinical sites and prescribers when they follow the specific post-meal dosing protocol within 15 minutes, paired with dosing leading to the claimed colon bioavailability outcomes (Claim 1).
Key Takeaways
- US 7,625,884 is a timing-and-outcome method patent: administer balsalazide within 15 minutes after eating to increase colon bioavailability of balsalazide, 5-ASA, and NASA versus fasting (Claim 1).
- Dependent claims broaden enforcement hooks through printed labeling (Claim 2) and informing patients (Claim 3), and specify dose regimens, food exemplars (applesauce, high-fat meal), and GI indications (ulcerative colitis, radiation proctosigmoiditis, colon cancer).
- The most material competitive design-around and litigation posture hinges on the meal-timing window (15 minutes) and whether the protocol produces an increase in colon bioavailability for the claimed analytes.
FAQs
-
Is US 7,625,884 a composition patent or a method patent?
It is a method of treating patent centered on administration timing with food and a colon bioavailability outcome.
-
What is the critical timing limitation in Claim 1?
Dosing must occur within 15 minutes after eating a meal.
-
Which analytes must show increased bioavailability to the colon?
Balsalazide, 5-ASA, and N-acetyl-5-ASA (NASA).
-
Do the dependent claims require specific foods?
Claim 8 provides exemplars: applesauce or a high-fat meal. Claim 1 itself requires “with food,” not a specified food type.
-
How do Claims 2 and 3 change enforcement leverage?
They add printed labeling requirements (Claim 2) and a step of informing the subject (Claim 3), expanding potential defendants to parties controlling instructions.
References
- US Patent 7,625,884 (claim text provided in prompt).
